Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
50%
Ph phase_4
1
25%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Other(1)

Detailed Status

Recruiting2
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (25.0%)
Phase 41 (25.0%)
N/A2 (50.0%)

Trials by Status

recruiting250%
completed125%
unknown125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_4

Dex & Mastectomy Pain

NCT07556952
recruitingnot_applicable

PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults

NCT07327931
unknownnot_applicable

Effect of Intravenous Versus Intrathecal Dexamethazone on Postdural Puncture Headache

NCT04709029
completedphase_3

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

NCT00366834

Clinical Trials (4)

Showing 4 of 4 trials
NCT07556952Phase 4

Dex & Mastectomy Pain

Recruiting
NCT07327931Not Applicable

PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults

Recruiting
NCT04709029Not Applicable

Effect of Intravenous Versus Intrathecal Dexamethazone on Postdural Puncture Headache

Unknown
NCT00366834Phase 3

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4